Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neuroblastoma 7Lymphoma, B-Cell 5Lymphoma 5Rhabdoid Tumor 3Neoplasms 3Medulloblastoma 3Leukemia, Myeloid, Acute 3Leukemia 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pinealoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms, Germ Cell and Embryonal 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Ganglioneuroblastoma 2Ependymoma 2Enteropathy-Associated T-Cell Lymphoma 2Brain Neoplasms 2Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1

Interventions

Cyclophosphamide 8Rituximab 5fludarabine 4Vincristine 4Prednisone 4Doxorubicin 4fludarabine phosphate 3Tacrolimus 3Mycophenolic Acid 3Etoposide 3Busulfan 3venetoclax 2entrectinib 2atezolizumab 2alectinib 2acalabrutinib 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Melphalan 2Bortezomib 2trametinib 1pertuzumab 1pembrolizumab 1obinutuzumab 1liposomal doxorubicin 1isatuximab 1ibrutinib 1etoposide phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × etoposide phosphate × 1 year × Clear all
NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Columbia University

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡